The global biopharma industry and the rise of Indian drug multinationals: Implications for Australian generics policy

Australia and New Zealand Health Policy

Volumn 4, Issue 1, 2007, Pages

  Löfgren, Hans ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DRUG; ESOMEPRAZOLE; GENERIC DRUG; HUMAN GROWTH HORMONE; OMEPRAZOLE; PROLOSEC; SERTRALINE; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; AUSTRALIA; BIOTECHNOLOGY; COMPETITION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; INDIA; PATENT; POLICY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PRICING;

EID: 34347366224     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-4-10     Document Type: Article

References (64)

1. OECD Biotechnology for Sustainable Growth and Development http://www.oecd.org/dataoecd/43/2/33784888.PDF
2. Benner M Lofgren H The Bio-Economy and the Competition State: Transcending the Dichotomy between Coordinated and Liberal Market Economies New Political Science 2007
3. Herper M Nagging Doubts for Big Pharma http://www.forbes.com/business/ 2006/07/25/pharma-profits-dangers-cz_mh_0726drug.html
4. Angell M The Truth About the Drug Companies Melbourne, Scribe Publications 2005
5. Law J Big Pharma: How the World's Biggest Drug Companies Control Illness London, Constable 2006
6. Cockburn IM Is the Pharmaceutical Industry in a Productivity Crisis? Paper prepared for the NBER Innovation Policy and the Economy Conference Washington DC, 2006
7. Gillies R T'hoen E Patients' Needs are What Must Drive Drug Research Financial Times London 2006
8. Cockburn IM The Changing Structure of the Pharmaceutical Industry Health Affairs 2004 23 10-22 10.1377/hlthaff.23.1.10 15002624
9. Frost & Sullivan Research Tackling Productivity Crisis in Drug Discovery Pharmabizcom http://www.pharmabiz.com/article/ detnews.asp?articleid=33361§ionid=50
10. Gray N Changing Landscape: A Special Report on the World's Top 50 Pharma Companies Pharmaceutical Executive 2006 2006 78-88
11. Lang Chu W New Study Reveals Pharma Market Grew 7 pc in 2005 http://www.drugresearcher.com/news/ng.asp?n=66620-ims-byetta-gardasil
12. Anonymous An Overdose of Bad News: The Drugs Industry The Economist 2005 374 73-75
13. Gassman O Reepmeyer G Organizing Pharmaceutical Innovation: From Science-based Knowledge Creators to Drug-oriented Knowledge Brokers Creativity and Innovation Management 2005 14 233-245 10.1111/ j.1467-8691.2005.00344.x
14. Sawant M Outsourcing: Shifting Paradigms http://www.pharmabiz.com/ article/detnews.asp?articleid=33676§ionid=50
15. Hess J Litalien S Battle for the Market: Branded Drug Companies' Secret Weapons that Generic Drug Makers Must Know Journal of Generic Medicines 2005 3 20-29 10.1057/palgrave.jgm.4940095
16. Roumeliotis G India Set to Overtake Italy in API Production http://www.drugresearcher.com/news/ng.asp?id=67610
17. van Arnum P Asian Producers Raise Their Profiles In the Global Pharmaceutical Value Chain Pharmaceutical Technology 2006 70-76
18. Cygnus Business Consulting & Research Biopharma Giving a Big Push to Indian Outsourcing Bid Industry Monitor Biopharmacueticals 2006 606 1-2
19. Quaiser M Mohan Chandran P Patent Era Spurs Drug Discovery - II Chronicle Pharmabiz 2006
20. Congressional Budget Office How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry Washington, Congress of the United States 1998
21. Lofgren H Generic drugs: International Trends and Policy Developments in Australia Australian Health Review 2004 27 39-48 15362295
22. Gray N Keeping pace with the Evolving Pharmaceutical Business Model Pharmaceutical Executive 2006
23. Class S Whither Generics?: Why Major Restructuring Lies Ahead Journal of Generic Medicines 2005 2 232-239 10.1057/palgrave.jgm.4940074
24. Humphreys A D'Amore N Generic Deluge Med Ad News 2005 24
25. Anonymous Generics Transform Statin Outlook Med Ad News 2006 12
26. Department of Health and Ageing Questions and Answers - Price Change for Atorvastatin (Lipitor®) in the 1 August Issue of the Schedule of Pharmaceutical Benefits http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/health-pbs-atorvastinqa#
27. St.Onge J Bristol, Sanofi Ask U.S. Judge to Halt Generic Form of Plavix http://www.bloomberg.com/apps/news?pid=20601103&sid= aWOk8WKMMxB0&refer=us#
28. Pierson R Apotex Says Deal Guards Generic Plavix, Sales Soar http://www.globeinvestor.com/servlet/story/ROC.20060821.2006- 08-21T221515Z_01_N21468137_RTRIDST_0_BUSINESS-PLAVIX-COL/GIStory/
29. Barr Pharmaceuticals Annual Report http://www.barrlabs.com/overview/ annual/index.php
30. Datamonitor Biogenerics: The Battle is Only Just Beginning Journal of Generic Medicines 2006 3 177-182 10.1057/palgrave.jgm.4940116
31. Alpert W Biotech's New Battlefield Barron's 2006 17
32. Houlton S Global Report: Moving Towards Generic Biologics http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=301751
33. Ladley E A Prescription for Future Success: Companies Should Begin Formulating Life-Cycle Strategies in Phase II of Development to Extend a Product's Revenue Med Ad News 2006 25
34. Federal Trade Commission Prepared Statement on Barriers to Generic Entry United States Senate, Special Committe on Aging Washington D.C., 2006
35. Sanofi-Aventis A Brand Dedicated to Generics http://en.sanofi-aventis.com/group/products/p_group_gen.asp
36. Probyn A Some Drugs More Equal Than Others: Pseudo-generics and Commercial Practice Australian Health Review 2004 28 207-217 15527401
37. Tempest B CEO Perspective: Meeting the Challenge of Growth and Profitability Journal of Generic Medicines 2005 2 297-307 10.1057/ palgrave.jgm.4940082
38. El Feki S Prescription for Change: A Survey of Pharmaceuticals The Economist 2005 18 June
39. Chaudhuri S The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries New Delhi, Oxford University Press 2005
40. Malhotra P Lofgren H India's Pharmaceutical Industry: Hype or High Tech Take-Off? Australian Health Review 2004 28 182-193 15527398
41. Lal UL Pharmaceutical Industry - India, a Giant in the Making http://biotechindustrystocks.com/III/News/062606.asp
42. Cygnus Business Consulting & Research Indian Pharmaceuticals: Industry Insight Hyderabad, Cygnus 2005
43. Matrix Laboratories Annual Report 2004-05 http://www.matrixlabsindia.com/ inside/annualreports.asp
44. Singh MM Will India Become the Global Centre for Pharmaceutical Research & Development? Journal of Generic Medicines 2006 3 194-200 10.1057/ palgrave.jgm.4940119
45. Roumeliotis G Ranbaxy's Thirst for European Generics Firms Proves Unquenchable in-Pharma Technologist.com 2006 http://www.in-pharmatechnologist.com/news/ng.asp?n=66800- ranbaxy-generics-terapia-glaxosmithkline-ethimed
46. Thomas P Ranbaxy Laboratories is Challenging Stereotypes and Changing Perceptions http://www.pharmamanufacturing.com/articles/2005/309.html
47. Rangnekar D No Pills for Poor People: Understanding the Disembowelment of India's Patent Regime Economic and Political Weekly 2006
48. Gehl Sampath P Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Market Maastricht, United Nations University-Institute for New Technologies (UNU-INTECH) 2005
49. Lanjouw JO Intellectual Property and the Availability of Pharmaceuticals in Poor Countries NBER Innovation Policy & the Economy 2003 3 91-129
50. Ford N Patents, Access to Medicines and the Role of Non-Governmental Organisations Journal of Generic Medicines 2004 1 137-145 10.1057/ palgrave.jgm.4940005
51. Sibal K Research in Pharmaceutical Industry http://164.100.24.208/lsq14/ quest.asp?qref=28223
52. Krishnan GS India Learns How to Discover Drugs Businessworld 2006 30-36
53. Mukherjee A Indian Drug Makers: Being a Copycat is Losing its Charm Business Line Hyderabad, 2005 11
54. Blaisdell P Outsourcing in Pharmaceutical Development BDMA Newsletter (Bulk Drug Manufacturers Association India) 2005 8-10
55. IDMA Global Bulk Drug Industry Hyderabad, Bulk Drug Manufacturers Association 2004
56. Stafford A Effective API Sourcing in Generic Pharmaceuticals Pharma & Bio Ingredients 2005 2 42-49
57. Anonymous Generic Drug Firms Eye Consolidation http://money.cnn.com/2005/ 06/22/news/midcaps/generics/
58. Department of Health and Ageing National Medicines Policy http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ nmp-objectives-policy.htm
59. Department of Health and Ageing New Pricing and Listing Arrangements for Generic Medicines on the Pharmaceutical Benefits Scheme (PBS) http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-pricereductions/$FILE/qamar05.pdf
60. Stafford A What Price Our Health The Age Melbourne, 2006 13
61. Breusch J Health Risks of Reform Exaggerated, Says Abbott Financial Review Sydney; 3 August 2006: 5
62. Faunce T Lofgren H Harvey K Johnston K Tendering for Low Cost Generics in Australia Health Issues 2006 26-29
63. Genepharm Australasia Prospectus Melbourne
64. Anonymous Biotechnology Asia Pacific Mergent Industry Reports Number 395 2006